Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014


ADC Summit 2014 London

19 May 2014 - 20 May 2014 - London, UK



Bookmark and Share


Making your smart bomb smarter - creating innovative antibody-drug conjugates

SMi’s 3rd annual Antibody Drug Conjugates Summit comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies.

Join us this May in London to hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

KEY REASONS TO ATTEND:

  • Hear cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challenges
  • Network and learn from industry and academic opinion leaders including Photobiotics, Medlmmune, Spirogen, Synthon plus many more…
  • Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)
  • Join the debate in our round table session to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal

KEY SPEAKERS WILL INCLUDE:

  • Dr Mahendra Deonarain, Chief Scientific Officer, Photobiotics
  • Dr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmune
  • Philip Howard, PhD, Chief Scientific Officer, Spirogen Limited
  • Dr Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
  • Dr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, Synthon
  • Dr Erica Hong, Scientist, ImmunoGen
  • Dr Hagop Youssoufian, Executive Vice President of R&D, Progenics
  • Dr Pamela Trail, Vice President Oncology, Regeneron

This 2 day networking event will invite in depth discussion of key drivers impacting ADCs, providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. 

To download a brochure and to secure your attendance visit http://www.smi-online.co.uk/goto/2014adcsummit36.asp 

Alternatively for further information contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk 



Further information
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!